The global bipolar disorder market was valued at USD 5.1 billion in 2025 and is projected to grow from USD 5.3 billion in 2026 to USD 6.4 billion in 2033, at a CAGR of 2.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.0% in 2025. The growth of this market is primarily driven by the increasing prevalence of bipolar disorder and rising government investments to enhance awareness and support advancements in healthcare and research institutions. Furthermore, rapid urbanization and evolving lifestyles have contributed to higher levels of stress and substance abuse, leading to a growing incidence of bipolar disorder. Consequently, the need for effective diagnosis, treatment, and long-term management is driving the market growth.
Bipolar disorder can occur due to various genetic and environmental factors, such as stressful life events, trauma, or emotional abuse, which can lead to the triggering of the condition. Due to changing lifestyles and an increase in stressful work environments, there is a rise in the diagnosis of bipolar disorders. Furthermore, increased awareness of bipolar disorders due to initiatives led by governments and NGOs has increased the number of patients seeking medical help to diagnose and treat their mental health. These initiatives have resulted in a change of perspective and the elimination of stigma related to bipolar disorders, which has further helped in the growth of this market.
Furthermore, substantial investments by leading medical institutes in research and development for bipolar disorder and its treatment have contributed to market growth. Therefore, there is an increase in the number of medicines available to treat bipolar disorders. Due to increased awareness, there is a rise in demand for diagnosis and medication for bipolar disorders. With the increase in the consumption of medicines related to bipolar disorders, companies are increasing the number of drugs in the market by getting approvals from regulatory bodies.
▪ Canada
▪ Mexico
▪ Germany
▪ France
▪ Italy
▪ Spain
▪ Denmark
▪ Sweden
▪ Norway
▪ China
▪ India
▪ Australia
▪ South Korea
▪ Thailand
▪ Argentina
▪ Saudi Arabia
▪ UAE
▪ Kuwait
This product will be delivered within 1-3 business days.
Bipolar disorder can occur due to various genetic and environmental factors, such as stressful life events, trauma, or emotional abuse, which can lead to the triggering of the condition. Due to changing lifestyles and an increase in stressful work environments, there is a rise in the diagnosis of bipolar disorders. Furthermore, increased awareness of bipolar disorders due to initiatives led by governments and NGOs has increased the number of patients seeking medical help to diagnose and treat their mental health. These initiatives have resulted in a change of perspective and the elimination of stigma related to bipolar disorders, which has further helped in the growth of this market.
Furthermore, substantial investments by leading medical institutes in research and development for bipolar disorder and its treatment have contributed to market growth. Therefore, there is an increase in the number of medicines available to treat bipolar disorders. Due to increased awareness, there is a rise in demand for diagnosis and medication for bipolar disorders. With the increase in the consumption of medicines related to bipolar disorders, companies are increasing the number of drugs in the market by getting approvals from regulatory bodies.
Global Bipolar Disorder Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities across each sub-segment from 2021 to 2033. For the purpose of this study, the analyst has segmented the global bipolar disorder market report based on type, drug class, distribution channel, and region:Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Mood stabilizer
- Anticonvulsants
- Antipsychotic drugs
- Antidepressant drugs
- Antianxiety drugs
- Other Types
Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
- Selective serotonin reuptake inhibitor
- Serotonin norepinephrine reuptake inhibitor
- Tricyclic antidepressant drugs
- Monoamine oxidase inhibitors
- Benzodiazepines
- Beta blockers
- Other Drug Classes
Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
▪ Canada
▪ Mexico
- Europe
▪ Germany
▪ France
▪ Italy
▪ Spain
▪ Denmark
▪ Sweden
▪ Norway
- Asia Pacific
▪ China
▪ India
▪ Australia
▪ South Korea
▪ Thailand
- Latin America
▪ Argentina
- Middle East and Africa (MEA)
▪ Saudi Arabia
▪ UAE
▪ Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Bipolar Disorder Market Variables, Trends, & Scope
Chapter 4. Bipolar Disorder Market: Type Estimates & Trend Analysis
Chapter 5. Bipolar Disorder Market: Drug Class Estimates & Trend Analysis
Chapter 6. Bipolar Disorder Market: Distribution Channel Estimates & Trend Analysis
Chapter 7. Bipolar Disorder Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
Companies Mentioned
- AstraZeneca
- Eli Lilly and Company
- GSK plc
- Johnson & Johnson Services, Inc.
- Pfizer Inc.
- AbbVie Inc.
- Otsuka Holdings Co., Ltd.
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd.
- Sumitomo Pharma America, Inc.
